Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform committed to breaking down barriers to safe and affordable healthcare, today announced access to the most common compounded GLP-1 subscriptions for as low as $99 a month for eligible U.S. military, veterans, teachers, nurses and first responders.

Providing access to safe, affordable weight loss solutions is more critical than ever yet many Americans do not have consistent access to these life-changing treatments. Hims & Hers is introducing the Service Appreciation Initiative to give eligible U.S. military, veterans, teachers, nurses and first responders the ability to benefit from compounded semaglutide GLP-1s at significantly lower costs.

GLP-1 medications can support healthy weight loss along with a reduced calorie diet and increased exercise by helping manage blood sugar levels, curb cravings and suppress appetite, so people eat less without feeling deprived. Hims & Hers offers a comprehensive weight loss solution personalized for individuals which may include compounded GLP-1 injections or oral weight loss medication kits as deemed appropriate by the healthcare provider.

Hims & Hers weight loss customers have seen tremendous success on weight loss treatments. Based upon self-reported data from approximately 12,000 customers subscribed to a comprehensive Hims & Hers weight loss offering, customers report having lost, on average, 10.2 pounds while on compounded GLP-1 injections and 6.3 pounds while on non-GLP-1 compounded oral medication kits, along with a reduced calorie diet and exercise, between their initial weight at consultation and their first check-in approximately 4 weeks later.

“The current state of access to weight loss drugs isn’t serving everyone who needs them,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “Safe and affordable healthcare solutions for every individual should be the status quo. This initiative has the potential to make a lasting impact in our communities by providing more reliable, consistent access to these life-changing medications for the millions of Americans who want a better, more affordable way to take care of their health.”

According to the World Health Organization (WHO), around 70% of American adults have obesity or are overweight and at least 2.8 million people die each year due to being overweight or having obesity.

  • In 2019, The National Health and Resilience in Veterans Study revealed that 32.7% of U.S. veterans have obesity. Veterans with obesity report poorer health status and more disability days compared to veterans without obesity.1
  • A recent study by Legg et al.2 reported that the monthly prevalence of obesity in U.S. active component military members ranged from 15.0% in August 2020 to 19.3% in April 2021, confirming a further growth trend.
  • Obesity is a significant health problem among teachers, with one study finding that 70.2% of female school teachers have obesity.3
  • 40% of police officers and firefighters have obesity and 80% are overweight. Occupational hazards like stress, sleep disruption, and shift work play a key role.4
  • Of all healthcare jobs, obesity rates were significantly higher with nurses compared to doctors, paramedics, technicians, and other medical roles.5

“When you’re giving so much to others, it can be hard to give back to yourself,” says Robin Seale, Hers Weight Loss Program customer. “Frontline healthcare workers, like me, have busy schedules, and it can feel daunting to go to the doctor’s office to get the care you need, and even more daunting when you can’t access it. I’m so thankful that Hims & Hers is making it easier for people like me to do something so important for our health by providing access to healthcare at an affordable price.”

In addition to providing access to weight loss treatment, Hims & Hers knows that the most effective care requires comprehensive, customizable treatment plans that address other underlying factors that affect people’s weight – including nutrition, behavior, and movement. Hims & Hers’ weight loss program takes a holistic approach to managing weight, with individual treatment plans personalized by licensed healthcare providers on the Hims & Hers platform catered to each individual’s specific needs.

Compounded GLP-1 injections are fulfilled and shipped from Hims & Hers’ affiliated pharmacies. The treatments customers receive from Hims & Hers will always come from a state-licensed, FDA-regulated facility. The company maintains high standards of safety and quality in their ingredients and transparency in operations.

For more information and details about eligibility and restrictions, visit http://hims.com/appreciation or http://forhers.com/appreciation.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.